Biological Trace Element Research

, Volume 29, Issue 3, pp 267–280 | Cite as

Nephrotoxicity and neurotoxicity in humans from organogermanium compounds and germanium dioxide

  • Alexander G. Schauss


There is no known biological requirement for germanium (Ge), germanates, or any organogermanium compound. Ge deficiency has not been demonstrated in any animal. The estimated average dietary intake of Ge in humans is 1.5 mg/d. Ge is widely distributed in edible foods, all of which, with few exceptions, contain less than 5 ppm Ge, since higher levels are toxic to most plants. Ingestion of Ge compounds has been shown to produce toxic effects in experimental animals.

In recent years inorganic germanium salts and novel organogermanium compounds, such as carboxyethyl germanium sesquioxide (Ge-132) and lactate-citrate-germanate (Ge lactate citrate) have been sold as “nutritional supplements” in some countries for their purported immunomodulatory effects or as health-producing elixirs, resulting sulting in intakes of Ge significantly exceeding the estimated average dietary intake. Since 1982, there have been 18 reported cases of acute renal dysfunction or failure, including two deaths, linked to oral intake of Ge elixirs containing germanium dioxide (GeO2) or Ge-132. In these cases, biopsies show vacuolar degeneration in renal tubular epithelial cells, without proteinuria or hematuria, in the absence of glomerular changes. Serum creatinine levels have been well above 400 μmol/L in such patients. In 17 of 18 cases, accumulated elemental Ge intakes reportedly ranged between 16 to 328 g over a 4–36 mo period, or between 100 to 2000 times the average estimated dietary intake for human. In surviving patients, renal function improved after discontinuation of Ge supplementation. However, in no case was recovery complete.

One organogermanium compound, an azaspiran organogermanium compound, 2-aza-8-germanspiro[4,5] decane-2-propamine-8,8-diethyl-N,N-dimethyl dichloride (spirogermanium), has been found to cause both neurotoxicity and pulmonary toxicity in phase I and II studies examining its chemotherapeutic potential as an antitumor drug in the treatment of various malignancies. In cancer patients given the drug spirogermanium, 40% experienced marked, yet transient neurotoxicity. Two patients suffered from pulmonary toxicity. Results of phases I and II human cancer trials for spirogermanium have not been favorable, with the exception of moderate benefits for three types of malignancies.

It is recommended that patients exposed to long-term (>3 mo) Ge supplementation at levels well above the estimated daily intake be medically supervised and monitored for potential renal-, pulmonaryor neurotoxicity. Further study regarding the mechanism of Geinduced nephrotoxicity in human is warranted.

Index Entries

Germanium germanium toxicity—humans germanium dioxide organogermanium compounds carboxyethyl germanium sesquioxide (Germanium-132 or Ge-132) spirogermanium germanium lactate citrate germanates acute renal failure resulting from germanium toxicity germanium-induced nephrotoxicity germanium neurotoxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. S. Dana,A Textbook of Mineralogy, 4th Ed., Wiley & Sons, New York, 1944.Google Scholar
  2. 2.
    W. L. Roberts, G. R. J. Rapp, and J. Weber,Encyclopedia of Minerals, Van Nostrand Reinhold, New York, 1974.Google Scholar
  3. 3.
    R. Schwarz and H. Scholz,Berichte d D Chem. Ges. 74, 1676–1679 (1941).CrossRefGoogle Scholar
  4. 4.
    H. A. Schroeder and J. J. Balassa,J. Chronic. Dis. 20, 211–224 (1967).PubMedCrossRefGoogle Scholar
  5. 5.
    E. I. Hamilton and M. J. Minski,Sci. Total. Environ. 1, 341–374 (1972/1973).CrossRefGoogle Scholar
  6. 6.
    W. S. Snyder, M. J. Cook, E. S. Nasset, L. R. Karhausen, G. P. Howells, and I. H. Tipton, inInternational Commission on Radiological Protection, ICRP, New York, 1975.Google Scholar
  7. 7.
    C. Reilly,Metal Contamination of Food, Applied Science Publishers, London, UK, 1980.Google Scholar
  8. 8.
    H. Matsumoto, S. Syo, and E. Takahasi,Soil Sci. Plant Nutr. 21, 273–280 (1975).Google Scholar
  9. 9.
    M._-K. Park and D._-S. Han,Soul Taehakkyo Yahhak Nonmunjip 4, 100–108 (1979).Google Scholar
  10. 10.
    M. Staufer,Erfahrungsheilkunde 29, 646–647 (1980).Google Scholar
  11. 11.
    P. D. Whanger inNutrition and Basic and Applied Science, J. N. Hatchcook, ed., Academic, New York, 1982, pp. 163–208.Google Scholar
  12. 12.
    G. Rosenfeld,Arch. Biochem. Biophys. 48, 84–94 (1954).PubMedCrossRefGoogle Scholar
  13. 13.
    G. Rosenfeld and E. J. Wallace,Arch. Indust. Hyg. Occup. Med. 8, 466–479 (1953).Google Scholar
  14. 14.
    V. Vouk, inHandbook on the Toxicology of Metals, L. Friberg, G. F. Nordberg, and V. Vouk, eds., Elsevier Science, Amsterdam, 1979, pp. 421–428.Google Scholar
  15. 15.
    V. Vouk, inHandbook on the Toxicology of Metals, 2nd Ed., L. Friberg, G. F. Nordberg, and V. Vouk, eds., Elsevier Science, Amsterdam, 1986, pp. 255–266.Google Scholar
  16. 16.
    B. Marczynski,Med. Hypotheses 26, 239–249 (1988).PubMedCrossRefGoogle Scholar
  17. 17.
    M. Hatano, K. Ishimura, and K. Fuchigami,Oyo Yakuri 21, 793–796 (1981).Google Scholar
  18. 18.
    O. Mogilevskaja, inProblems of Industial Hygiene and Occupational Pathology in Work with Rare Metals. Z. I. Israel’son, O. Mogilevsskaja, and S. V. Suvorov, eds., Medicina, Moscow, 1973, pp. 227–239.Google Scholar
  19. 19.
    H. C. Dudley and E. J. Wallace,Arch. Ind. Hyg. Occup. Med. 6, 263–270 (1952).Google Scholar
  20. 20.
    L. M. Rice, J. M. Wheeler, and C. F. Geschickter,J. Heterocyl. Chem. 11, 1041–1047 (1974).CrossRefGoogle Scholar
  21. 21.
    K. Pinnamaneni, H._-Y. Yap, S. S. Legha, G. R. Blumenschein, and G. P. Bodey,Cancer Treat. Rep. 68, 1197–1198 (1984).PubMedGoogle Scholar
  22. 22.
    N.J. Volgelzang, D. H. Gesme, and B. J. Kennedy,Am. J. Clin. Oncol. 8, 341–344 (1985).CrossRefGoogle Scholar
  23. 23.
    P. Schulman, R. B. Davis, S. Rafla, M. Green, and E. Henderson,Cancer Treat. Rep. 68, 1305, 1306 (1984).PubMedGoogle Scholar
  24. 24.
    D. E. Brenner, N. B. Rosenshein, M. Dillon, H. W. Jones, A. Forastiere, S. Tipping, L. S. Burnett, F. A. Greco, and P. H. Wiernik,Cancer Treat. Rep. 69, 457, 458 (1985).PubMedGoogle Scholar
  25. 25.
    K. Asai,Miracle Cure Organic Germanium, K. Asai Japan Publications, Tokyo, 1980.Google Scholar
  26. 26.
    M. Tsutsui, D. Kakimoto, D. Axtell, H. Oikawa, and K. Asai,J. Am. Chem. Soc. 98, 8287–8289 (1976).CrossRefGoogle Scholar
  27. 27.
    N. Kumano, Y. Nakai, T. Kshikawa, S. Koinumaru, S. Suzuki, and K. Konno,Sci. Rep. Res. Inst. Tohoku Univ. 25, 89–95 (1978).Google Scholar
  28. 28.
    H. Sato and T. Iwaguchi,Gan To Kagaku Ryoho (Japan J. Cancer Chemotherapy) 6, 79–83 (1979).Google Scholar
  29. 29.
    H. Aso, Y. Hayashi, F. Suzuki, and N. Ishida,Proc. Jap. Cancer Assn. 38, 112–115 (1979).Google Scholar
  30. 30.
    T. Suzuki. S. Ishikawa, T. Motoyama, and Oboshi,Acta. Pathol. Jap. 30, 557–564 (1980).Google Scholar
  31. 31.
    K. Shimpo and N. Mori,Phamacometrics (Japan) 20, 675–679 (1980).Google Scholar
  32. 32.
    K. Miyao, inImmunomodulation by Microbial Products and Related Synthetic Compounds, Y. Yamamura, and S. Kotani, eds., Elsevier, Amsterdam, 1981, pp. 536–539.Google Scholar
  33. 33.
    N. Kumano, Y. Nakai, T. Ishikawa, S. Koinumaru, S. Suzuki, T. Kikumoto, S. Takizawa, K. Miyao, and K. Konno,Sci. Rep. Res. Inst. Tohoku Univ. 25, 89–95 (1978).Google Scholar
  34. 34.
    F. Suzuki,Gan to Kagaku Ryoho (Japan J. Cancer Chemotherapy) 12, 2122–2188 (1985).Google Scholar
  35. 35.
    I. Sato, B. Yuan, T. Nishimua, and N. Tanaka,J. Bio. Response Modifiers 4, 159–168 (1985).Google Scholar
  36. 36.
    H. Aso, E. Shibuya, F. Susuki, T. Nakamurea, H. Inoue, T. Ebina, and N. Ishida,Gan To Kagaku Ryoho (Japan J. Cancer Chemotherapy) 12, 2345–2351 (1985).Google Scholar
  37. 37.
    F. Suzuki, R. R. Brutkiewicz, and R. B. Pollard,Brit. J. Cancer 52, 757–764 (1985).PubMedGoogle Scholar
  38. 38.
    H. Kobayashi, T. Komuro, and H. Furue,Gan To Kagaku Ryoho (Japan J. Cancer Chemotherapy) 13, 2588–2593 (1986).Google Scholar
  39. 39.
    F. Susuki, R. R. Brutkiewicz, and R. B. Pollard,Anticancer Res. 6, 177–182 (1986).Google Scholar
  40. 40.
    F. Susuki,Gan To Kagaku Ryoho (Japan J. Cancer Chemotherapy) 14, 127–134 (1987).Google Scholar
  41. 41.
    P. S. Schein, M. Slavik, T. Smythe, D. Hoth, F. Smith, J. S. Macdonald, and P. V. Woolley,Cancer Treat. Rep. 64, 1051–1056 (1980).PubMedGoogle Scholar
  42. 42.
    S. S. Legha, J. A. Ajani, and G. P. Bodey,J. Clin. Oncol. 1, 331–336 (1983).PubMedGoogle Scholar
  43. 43.
    C. Trope, W. Mattsson, I. Gynning, J.-E. Johnson, K. Sigurdsson, and B. Orbert,Cancer Treat. Rep. 65, 119, 120 (1981).PubMedGoogle Scholar
  44. 44.
    G. Falkson and H. C. Falkson,Cancer Treat. Rep. 67, 189, 190 (1983).PubMedGoogle Scholar
  45. 45.
    J. P. Kuebler, D. C. Tormey, G. R. Harper, Y.-C. Chang, J. D. Khandekar, and G. Falkson,Cancer Treat. Rep. 68, 1515, 1516 (1984).PubMedGoogle Scholar
  46. 46.
    J. J. Kavanagh, P. B. Saul, L. J. Copeland, D. M. Gershenson, and I. H. Krakoff,Cancer Treat. Rep. 69, 139, 140 (1985).PubMedGoogle Scholar
  47. 47.
    C. Dixon, F. Hegemeister, S. Legha, and G. Bodey,Cancer Treat. Rep. 68, 907, 908 (1984).PubMedGoogle Scholar
  48. 48.
    B. T. Hill, S. A. Whatley, A. S. Bellamy, L. Y. Jenkins, and R. D. H. Whelan,Cancer Res. 42, 2852–2856 (1982).PubMedGoogle Scholar
  49. 49.
    D. R. Budman, P. Schulman, V. Vinciguerra, and T. J. Degnan,Cancer Treat. Rep. 66, 173–175 (1982).PubMedGoogle Scholar
  50. 50.
    K. Loren,The Report on Germanium, Life Extension Educational Service, Glendale, CA, 1987.Google Scholar
  51. 51.
    B. Kamen,Germanium, A New Approach to Immunity, Nutrition Encounter, Larkspur, CA, 1987.Google Scholar
  52. 52.
    Y. Mizushima, Y. Shoji, and K. Kaneko,Int. Arch. Allergy Appl. Immunol. 63, 338, 339 (1980).PubMedGoogle Scholar
  53. 53.
    S. Goodman,Med. Hypotheses 26, 207–215 (1988).PubMedCrossRefGoogle Scholar
  54. 54.
    N. J. Vagelzang, D. H. Gesme, and B. J. Kennedy,Am J. Clin. Oncol. 8, 341–344 (1985).CrossRefGoogle Scholar
  55. 55.
    H. A. Schroeder, M. Kanisawa, D. V. Frost, and M. Mitchener,J. Nutr. 96, 37–45 (1968).Google Scholar
  56. 56.
    I. Yoneyama,Nippon Jinzo Gakkaishi 24, 1355, 1356 (1982).Google Scholar
  57. 57.
    N. Nagata, T. Yoneyama, K. Yanagida, K. Ushio, S. Yanagihara, O. Matsubara, and Y. Eishi,J. Toxicol. Sci. 10, 333–341 (1985).PubMedGoogle Scholar
  58. 58.
    M. Omata, M. Kikuchi, C. Higuchi, S. Sanaka, T. Takuma, N. Sugino, and Y. Mori, inNephrotoxicity of Antibiotics and Immunosuppressants, T. Tanabe, J. B. Hook, and H. Endou, eds., Elsevier, Amsterdam, 1986, pp. 15–20.Google Scholar
  59. 59.
    K. Okagawa, M. Kosaka, T. Sakikawa, M. Hiasa, H. Sato, K. Morizumi, H. Morita, S. Simomura, and S. Saito,Naika (Japan Arch. Int. Med.) 58, 1211–1214 (1986).Google Scholar
  60. 60.
    S. Okuda, S. Kiyama, Y. Oh, K. Simamatsu, N. Oochi, K. Kobayashi, F. Nanishi, S. Fujimi, K. Onoyama, and M. Fujishima,Curr. Ther. Res. 41, 265–275 (1987).Google Scholar
  61. 61.
    T. Matsusaki, M. Fujii, T. Nakano, T. Terai, A. Kurata, M. Imaizumi, and and H. Abe,Clin. Nephrol. 30, 341–345 (1988).Google Scholar
  62. 62.
    T. Nakano, M. Fuki, T. Terai, T. Matsuzaka, M. Kimura, and T. Toyomasu,J. Clin. Electron Microscopy 20, 850, 851 (1987).Google Scholar
  63. 63.
    R. Muller and Iszard,Am. J. Med. Sci. 163, 364–372 (1922).CrossRefGoogle Scholar
  64. 64.
    W. C. Hueper,Am. J. Med. Sci. 181, 820–830 (1931).CrossRefGoogle Scholar
  65. 65.
    K. Okada, K. Okagawa, K. Kawadami, Y. Kuroda, K. Morizumi, H. Sato, H. Morita, S. Shimomura, and S. Saito,Clin. Nephrol. 31, 219–224 (1989).PubMedGoogle Scholar
  66. 66.
    J. I. Van der Spoel, B. H. Stricker, M. R. Esseveld, and M. E. I. Schipper,Lancet ii, 117 (1990).Google Scholar
  67. 67.
    B. H. Stricker,Lancet 337, 864 (1991).PubMedCrossRefGoogle Scholar
  68. 68.
    E. Browning,Toxicity of Industrial Metals, 2nd Ed., Butterworths, London, UK, 1969.Google Scholar
  69. 69.
    K. Asai, Asai Germanium Research Institute, 1984, pp. 1–17.Google Scholar
  70. 70.
    S. Tomizawa, N. Suguro, and M. Kagoshima,Oyo Yakuri (Japan J. Appl. Pharmacol.) 16, 671–682 (1978).Google Scholar
  71. 71.
    K. Miyao, T. Onishi, K. Asai, S. Tomizawa, and F. Suziki, inProceedings of the 11th ICC and the 19th ICAAC, American Society of Microbiology, 1980, pp. 1527–1529.Google Scholar
  72. 72.
    H. E. Stokinger, inPatty’s Industrial Hygiene and Toxicology, G. D. Clayton and F. E. Clayton, eds., John Wiley, New York, 1981, p. 1493.Google Scholar
  73. 73.
    A. G. Schauss,Renal Failure 13, 1–4 (1991).PubMedCrossRefGoogle Scholar
  74. 74.
    Seizure actions.FDA Consumer 24, 37, 1990.Google Scholar
  75. 75.
    Seizure actions.FDA Consumer 24, 45, 1990.Google Scholar
  76. 76.
    R. Krapf,Schweiz Apoth Ztg 129, 10 (1991).Google Scholar

Copyright information

© The Humana Press, Inc 1991

Authors and Affiliations

  • Alexander G. Schauss
    • 1
  1. 1.Life Sciences DivisionAmerican Institute for Biosocial Research, Inc.Tacoma

Personalised recommendations